Traws Pharma, Inc. — Director's Dealing 2023

Mar 15, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Onconova Therapeutics, Inc. (ONTX)
CIK: 0001130598
Period of Report: 2023-03-13

Reporting Person: Guerin Mark Patrick (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-03-13	Stock Option (right to purchase)	$0.73	A	79000	Acquired	2033-03-13	Common Stock (79000)	Direct
2023-03-13	Restricted Stock Units	$	A	26000	Acquired		Common Stock (26000)	Direct

Footnotes

F1: These options vest over three years, one-third on the first anniversary of the date of grant and thereafter in 24 equal monthly installments over the following two years.

F2: Each restricted stock unit is convertible into one share of common stock.

F3: These restricted stock units vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34 % on the third anniversary